# Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP

> **NCT00144534** · PHASE3 · COMPLETED · sponsor: **Chugai Pharmaceutical** · enrollment: 115 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** MRA (Tocilizumab)

## Key facts

- **NCT ID:** NCT00144534
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2005-08
- **Final completion:** 2009-06
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2009-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00144534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00144534, "Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00144534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*